ABL1 and acute lymphoblastic leukemia: To determine whether plasma dasatinib pharmacokinetics influences BCR-ABL mutations , we used high-performance liquid chromatography (HPLC) to measure the plasma dasatinib concentrations in Ph + ALL patients undergoing dasatinib monotherapy.